Engineering CAR-T therapies for autoimmune disease and beyond.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 39475572.
- Also identified by DOI 10.1126/scitranslmed.ado2084.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chimeric antigen receptor-T cell (CAR-T) therapy has transformed the management of refractory hematological malignancies. Now that targeting pathogenic cells of interest with antigen-directed cytotoxic T lymphocytes is possible, the field is expanding the reach of CAR-T therapy beyond oncology. Recently, breakthrough progress has been made in the application of CAR-T technology to autoimmune diseases, exploiting the same validated targets that were used by pioneering CAR-T therapies in hematology. Here, we discuss recent advances and outcomes that are paving the way for extension to new therapeutic areas, including autoimmunity.
Medical subject headings
- Autoimmune Diseases
- Receptors, Chimeric Antigen
- Immunotherapy, Adoptive